Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 2
2005 5
2006 2
2007 1
2008 4
2009 4
2010 13
2011 12
2012 10
2013 12
2014 16
2015 18
2016 28
2017 39
2018 35
2019 34
2020 52
2021 61
2022 84
2023 66
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

460 results

Results by year

Filters applied: . Clear all
Page 1
Roxadustat: Not just for anemia.
Zhu X, Jiang L, Wei X, Long M, Du Y. Zhu X, et al. Front Pharmacol. 2022 Aug 29;13:971795. doi: 10.3389/fphar.2022.971795. eCollection 2022. Front Pharmacol. 2022. PMID: 36105189 Free PMC article. Review.
SARS-CoV-2 restructures host chromatin architecture.
Wang R, Lee JH, Kim J, Xiong F, Hasani LA, Shi Y, Simpson EN, Zhu X, Chen YT, Shivshankar P, Krakowiak J, Wang Y, Gilbert DM, Yuan X, Eltzschig HK, Li W. Wang R, et al. Among authors: zhu x. Nat Microbiol. 2023 Apr;8(4):679-694. doi: 10.1038/s41564-023-01344-8. Epub 2023 Mar 23. Nat Microbiol. 2023. PMID: 36959507 Free PMC article.
Emerging early diagnostic methods for acute kidney injury.
Xiao Z, Huang Q, Yang Y, Liu M, Chen Q, Huang J, Xiang Y, Long X, Zhao T, Wang X, Zhu X, Tu S, Ai K. Xiao Z, et al. Among authors: zhu x. Theranostics. 2022 Mar 21;12(6):2963-2986. doi: 10.7150/thno.71064. eCollection 2022. Theranostics. 2022. PMID: 35401836 Free PMC article. Review.
Enhancer RNA m6A methylation facilitates transcriptional condensate formation and gene activation.
Lee JH, Wang R, Xiong F, Krakowiak J, Liao Z, Nguyen PT, Moroz-Omori EV, Shao J, Zhu X, Bolt MJ, Wu H, Singh PK, Bi M, Shi CJ, Jamal N, Li G, Mistry R, Jung SY, Tsai KL, Ferreon JC, Stossi F, Caflisch A, Liu Z, Mancini MA, Li W. Lee JH, et al. Among authors: zhu x. Mol Cell. 2021 Aug 19;81(16):3368-3385.e9. doi: 10.1016/j.molcel.2021.07.024. Epub 2021 Aug 9. Mol Cell. 2021. PMID: 34375583 Free PMC article.
Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate Vγ9Vδ2 T cells.
Yuan L, Ma X, Yang Y, Qu Y, Li X, Zhu X, Ma W, Duan J, Xue J, Yang H, Huang JW, Yi S, Zhang M, Cai N, Zhang L, Ding Q, Lai K, Liu C, Zhang L, Liu X, Yao Y, Zhou S, Li X, Shen P, Chang Q, Malwal SR, He Y, Li W, Chen C, Chen CC, Oldfield E, Guo RT, Zhang Y. Yuan L, et al. Among authors: zhu x. Nature. 2023 Sep;621(7980):840-848. doi: 10.1038/s41586-023-06525-3. Epub 2023 Sep 6. Nature. 2023. PMID: 37674084 Free PMC article.
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, Wang Y, Wang S, Geng C, Luo T, Zhong J, Zhang Q, Liu Q, Zeng X, Sun T, Mo Q, Liu H, Cheng Y, Cheng J, Wang X, Nie J, Yang J, Wu X, Wang X, Li H, Ye C, Dong F, Wu S, Zhu X, Xu B; PHILA Investigators. Ma F, et al. Among authors: zhu x. BMJ. 2023 Oct 31;383:e076065. doi: 10.1136/bmj-2023-076065. BMJ. 2023. PMID: 37907210 Free PMC article. Clinical Trial.
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, Verschraegen C, Stover DG, Kaklamani V, Wang ZH, Shao ZM. Jiang YZ, et al. Among authors: zhu x. Cell Res. 2021 Feb;31(2):178-186. doi: 10.1038/s41422-020-0375-9. Epub 2020 Jul 27. Cell Res. 2021. PMID: 32719455 Free PMC article. Clinical Trial.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, Hu X, Cheng Y, Yan M, Pan Y, Teng Y, Yan X, Wang Y, Xie W, Zeng X, Wang X, Hu C, Geng C, Zhang H, Li W, Wu X, Zhong J, Xu J, Shi Y, Wei W, Bayaxi N, Zhu X, Xu B. Zhang P, et al. Among authors: zhu x. Lancet Oncol. 2023 Jun;24(6):646-657. doi: 10.1016/S1470-2045(23)00172-9. Epub 2023 May 11. Lancet Oncol. 2023. PMID: 37182538 Clinical Trial.
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J, Wang K, Liu Y, Wang H, Fu P, Zhang S, Liu Q, Wang S, Huang J, Wang C, Wang S, Wang Y, Zhen L, Zhu X, Wu F, Lin X, Zou J. Wu J, et al. Among authors: zhu x. BMC Med. 2022 Dec 27;20(1):498. doi: 10.1186/s12916-022-02708-3. BMC Med. 2022. PMID: 36575513 Free PMC article. Clinical Trial.
460 results